Intervention

lamivudine

ClinicalTrials.gov intervention label

Clinical trials11

Recruiting0

Common conditions5

Lead sponsors shown9

Clinical trials

11 shown

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian FederationNCT02581202 · 2015-12-21

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug ExposureNCT02263326 · 2014-12-01

Test Albuvirtide in Experienced PatientsNCT02369965 · 2014-02-19

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsNCT00915655 · 2009-07-01

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV InfectionNCT00612898 · 2008-02-01

Strategies for Delivering Anti-HIV Therapy in South AfricaNCT00080522 · 2005-02-01

2NN & CHARM Long-Term Follow-up StudyNCT00127972 · 2004-02-01

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)NCT00158470 · 2003-09-01

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsNCT00046176 · 2002-08-26

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsNCT00044577 · 2002-07-16

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination RegimenNCT00014937

Common conditions

HIV Infections5 HIV Infection4 HIV-1 Infection2 Infection, Human Immunodeficiency Virus I2 AIDS1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)2 ViiV Healthcare2 AbbVie1 Avexa1 Babafemi Taiwo1 French National Agency for Research on AIDS and Viral Hepatitis1 Frontier Biotechnologies Inc.1 International Antiviral Therapy Evaluation Center1 Tibotec Pharmaceuticals, Ireland1

Trial status mix

COMPLETED10

TERMINATED1

Phase mix

PHASE36

NA2

PHASE22

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.